Addendum zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus-Infektion“

• Literatur

• 1 Sarrazin C, Zimmermann T, Berg T. et al. Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection – AWMF-Register-No.: 021/012. Z Gastroenterol 2018; 56: 756-838
• 2 [Anonym]. https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/ ; https://www.bundesregierung.de/breg-de/service/publikationen/bis-2030-strategie-zur-eindaemmung-von-hiv-hepatitis-b-und-c-und-anderen-sexuell-uebertragbaren-infektionen-730444
• 3 Heffernan A, Cooke GS, Nayagam S. et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet (London, England) 2019; 393: 1319-1329
• 4 Bourliere M, Gordon SC, Flamm SL. et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017; 376: 2134-2146
• 5 Sarrazin C, Cooper CL, Manns MP. et al. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients. J Hepatol 2018; 69: 1221-1230